Institutional members access full text with Ovid®

Share this article on:

Rethinking osteoporosis: Balancing risk and benefit in diagnosis, prevention, and treatment

Smith, Alice MMS, PA-C; Shaw, Brittany MMS, PA-C; Laliberte, Danielle MMS, PA-C; Langston, Jennifer MMS, PA-C; Bushardt, Reamer L. PharmD, PA-C

Journal of the American Academy of PAs: August 2013 - Volume 26 - Issue 8 - p 20–27
doi: 10.1097/01.JAA.0000432496.47021.62
Endocrinology

ABSTRACT The standard of care for osteoporosis is changing amid questions about the long-term safety and efficacy of current drugs for preventing and treating osteoporosis. This article provides a guide for evidence-based treatment, but not overtreatment, as well as the selection and duration of available drug therapies.

Alice Smith, Brittany Shaw, Danielle Laliberte, and Jennifer Langston are recent graduates of the PA program at Wake Forest School of Medicine in Winston-Salem, North Carolina. Reamer Bushardt is professor and chair of the PA program at Wake Forest School of Medicine and editor in chief of JAAPA. The authors have indicated no relationships to disclose relating to the content of this article.

Earn Category I CME Credit by reading this article and the article beginning on page 28 and successfully completing the posttest on page 34. Successful completion is defined as a cumulative score of at least 70% correct. This material has been reviewed and is approved for 1 hour of clinical Category I (Preapproved) CME credit by the AAPA. The term of approval is for 1 year from the publication date of August 2013.

© 2013 American Academy of Physician Assistants.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website